PROMETHEUS BIOSCIENCES INC (RXDX) Fundamental Analysis & Valuation

NASDAQ:RXDX • US74349U1088

Current stock price

199.92 USD
+0.18 (+0.09%)
At close:
199.95 USD
+0.03 (+0.02%)
After Hours:

This RXDX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. RXDX Profitability Analysis

1.1 Basic Checks

  • RXDX had negative earnings in the past year.
  • RXDX had a negative operating cash flow in the past year.
RXDX Yearly Net Income VS EBIT VS OCF VS FCFRXDX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 -50M -100M

1.2 Ratios

  • RXDX has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
RXDX Yearly ROA, ROE, ROICRXDX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 -100 -200 -300 -400

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for RXDX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RXDX Yearly Profit, Operating, Gross MarginsRXDX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 -1K -2K -3K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. RXDX Health Analysis

2.1 Basic Checks

  • RXDX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, RXDX has more shares outstanding
  • RXDX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
RXDX Yearly Shares OutstandingRXDX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 10M 20M 30M 40M
RXDX Yearly Total Debt VS Total AssetsRXDX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 200M 400M 600M

2.2 Solvency

  • An Altman-Z score of 94.07 indicates that RXDX is not in any danger for bankruptcy at the moment.
  • With an excellent Altman-Z score value of 94.07, RXDX belongs to the best of the industry, outperforming 99.20% of the companies in the same industry.
  • There is no outstanding debt for RXDX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 94.07
ROIC/WACCN/A
WACC8.62%
RXDX Yearly LT Debt VS Equity VS FCFRXDX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 0 200M 400M 600M

2.3 Liquidity

  • A Current Ratio of 37.56 indicates that RXDX has no problem at all paying its short term obligations.
  • With an excellent Current ratio value of 37.56, RXDX belongs to the best of the industry, outperforming 98.56% of the companies in the same industry.
  • RXDX has a Quick Ratio of 37.56. This indicates that RXDX is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 37.56, RXDX belongs to the top of the industry, outperforming 98.56% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 37.56
Quick Ratio 37.56
RXDX Yearly Current Assets VS Current LiabilitesRXDX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. RXDX Growth Analysis

3.1 Past

  • RXDX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -26.62%.
  • Looking at the last year, RXDX shows a very negative growth in Revenue. The Revenue has decreased by -36.47% in the last year.
  • RXDX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 82.51% yearly.
EPS 1Y (TTM)-26.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-4.88%
Revenue 1Y (TTM)-36.47%
Revenue growth 3Y82.51%
Revenue growth 5YN/A
Sales Q2Q%-71.8%

3.2 Future

  • The Earnings Per Share is expected to grow by 22.32% on average over the next years. This is a very strong growth
  • The Revenue is expected to grow by 145.93% on average over the next years. This is a very strong growth
EPS Next Y-16.9%
EPS Next 2Y-15.66%
EPS Next 3Y-15.77%
EPS Next 5Y22.32%
Revenue Next Year-69.44%
Revenue Next 2Y-47.62%
Revenue Next 3Y136.24%
Revenue Next 5Y145.93%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
RXDX Yearly Revenue VS EstimatesRXDX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 500M 1B 1.5B 2B 2.5B
RXDX Yearly EPS VS EstimatesRXDX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 5 -5 10 15 20

More info and screens

Find the best growth stocksShow best growing peers

0

4. RXDX Valuation Analysis

4.1 Price/Earnings Ratio

  • RXDX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year RXDX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RXDX Price Earnings VS Forward Price EarningsRXDX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RXDX Per share dataRXDX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

  • A cheap valuation may be justified as RXDX's earnings are expected to decrease with -15.77% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-15.66%
EPS Next 3Y-15.77%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. RXDX Dividend Analysis

5.1 Amount

  • RXDX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

RXDX Fundamentals: All Metrics, Ratios and Statistics

PROMETHEUS BIOSCIENCES INC

NASDAQ:RXDX (6/15/2023, 8:23:19 PM)

After market: 199.95 +0.03 (+0.02%)

199.92

+0.18 (+0.09%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-09
Earnings (Next)N/A
Inst Owners0.05%
Inst Owner Change0%
Ins Owners24.07%
Ins Owner Change0%
Market Cap9.56B
Revenue(TTM)4.00M
Net Income(TTM)-150.56M
Analysts72
Price Target198.9 (-0.51%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)5.83%
Min EPS beat(2)4.21%
Max EPS beat(2)7.45%
EPS beat(4)4
Avg EPS beat(4)5.45%
Min EPS beat(4)2.44%
Max EPS beat(4)7.69%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)62.01%
Min Revenue beat(2)10.55%
Max Revenue beat(2)113.47%
Revenue beat(4)4
Avg Revenue beat(4)78.91%
Min Revenue beat(4)10.55%
Max Revenue beat(4)143.73%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)22.15%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-3.23%
EPS NY rev (1m)0%
EPS NY rev (3m)-4.65%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)9.82%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2392.69
P/FCF N/A
P/OCF N/A
P/B 13.7
P/tB 13.7
EV/EBITDA N/A
EPS(TTM)-3.52
EYN/A
EPS(NY)-4.66
Fwd EYN/A
FCF(TTM)-2.84
FCFYN/A
OCF(TTM)-2.79
OCFYN/A
SpS0.08
BVpS14.59
TBVpS14.59
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 293.94%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 37.56
Quick Ratio 37.56
Altman-Z 94.07
F-Score3
WACC8.62%
ROIC/WACCN/A
Cap/Depr(3y)350.62%
Cap/Depr(5y)510.37%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-26.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-4.88%
EPS Next Y-16.9%
EPS Next 2Y-15.66%
EPS Next 3Y-15.77%
EPS Next 5Y22.32%
Revenue 1Y (TTM)-36.47%
Revenue growth 3Y82.51%
Revenue growth 5YN/A
Sales Q2Q%-71.8%
Revenue Next Year-69.44%
Revenue Next 2Y-47.62%
Revenue Next 3Y136.24%
Revenue Next 5Y145.93%
EBIT growth 1Y-50.8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-36.98%
EBIT Next 3Y-23.62%
EBIT Next 5Y28.62%
FCF growth 1Y-94.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-94.09%
OCF growth 3YN/A
OCF growth 5YN/A

PROMETHEUS BIOSCIENCES INC / RXDX Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for PROMETHEUS BIOSCIENCES INC?

ChartMill assigns a fundamental rating of 4 / 10 to RXDX.


What is the valuation status for RXDX stock?

ChartMill assigns a valuation rating of 0 / 10 to PROMETHEUS BIOSCIENCES INC (RXDX). This can be considered as Overvalued.


What is the profitability of RXDX stock?

PROMETHEUS BIOSCIENCES INC (RXDX) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for RXDX stock?

The Earnings per Share (EPS) of PROMETHEUS BIOSCIENCES INC (RXDX) is expected to decline by -16.9% in the next year.